Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners

Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…

Behrad Derakhshan net worth and biography

Behrad Derakhshan Biography and Net Worth

Chief Business Officer of Edgewise Therapeutics

Behrad Derakhshan, Ph.D. has served as Chief Business Officer since September 2020 and leads Edgewise’s efforts in strategic planning, business development, capital formation, investor relations, commercial and competitive intelligence. Prior to joining Edgewise, Dr. Derakhshan was Chief Business Officer at VectivBio after having served as the Head of Business Development at Therachon, until its acquisition by Pfizer Inc. in 2019 for $810 million. Prior to Therachon, Dr. Derakhshan was responsible for Business Development and Strategic Evaluation at Alexion. Earlier in his career, Dr. Derakhshan worked in management consulting with a focus on rare disease drug development. Dr. Derakhshan serves on the board of Innoskel, a private biotechnology company developing therapies for rare bone diseases. Dr. Derakhshan conducted his postdoctoral training at the Yale School of Medicine and received his Ph.D. in biochemistry from a joint program between Weill Cornell Medicine, New York and the University of Surrey, UK.

What is Behrad Derakhshan's net worth?: The estimated net worth of Behrad Derakhshan is at least $428,832.90 as of May 2nd, 2024. Dr. Derakhshan owns 13,422 shares of Edgewise Therapeutics stock worth more than $428,833 as of November 20th. This net worth estimate does not reflect any other assets that Dr. Derakhshan may own. Additionally, Dr. Derakhshan receives a salary of $630,670.00 as Chief Business Officer at Edgewise Therapeutics. Learn More about Behrad Derakhshan's net worth.
How old is Behrad Derakhshan?: Dr. Derakhshan is currently 44 years old. There are 8 older executives and no younger executives at Edgewise Therapeutics. The oldest executive at Edgewise Therapeutics is Dr. Joanne M. Donovan M.D., Ph.D., Chief Medical Officer, who is 67 years old. Learn More on Behrad Derakhshan's age.
What is Behrad Derakhshan's salary?: As the Chief Business Officer of Edgewise Therapeutics, Inc., Dr. Derakhshan earns $630,670.00 per year. There are 3 executives that earn more than Dr. Derakhshan. The highest earning executive at Edgewise Therapeutics is Dr. Kevin Koch Ph.D., President, CEO & Director, who commands a salary of $905,520.00 per year. Learn More on Behrad Derakhshan's salary.
How do I contact Behrad Derakhshan?: The corporate mailing address for Dr. Derakhshan and other Edgewise Therapeutics executives is 3415 COLORADO AVE., BOULDER CO, 80303. Edgewise Therapeutics can also be reached via phone at 720-262-7002 and via email at [email protected]. Learn More on Behrad Derakhshan's contact information.
Has Behrad Derakhshan been buying or selling shares of Edgewise Therapeutics?: Behrad Derakhshan has not been actively trading shares of Edgewise Therapeutics during the last ninety days. Most recently, Behrad Derakhshan sold 1,718 shares of the business's stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $18.91, for a transaction totalling $32,487.38. Following the completion of the sale, the insider now directly owns 13,422 shares of the company's stock, valued at $253,810.02. Learn More on Behrad Derakhshan's trading history.
Who are Edgewise Therapeutics' active insiders?: Edgewise Therapeutics' insider roster includes R. Michael Carruthers (CFO), Behrad Derakhshan (Chief Business Officer), Joanne Donovan (CMO), Jonathan Fox (Director), Kevin Koch (President, CEO and Director), John Moore (General Counsel), Jonathan Root (Director), Alan Russell (Insider), and Peter Thompson (Chairman and Co-Founder). Learn More on Edgewise Therapeutics' active insiders.
Are insiders buying or selling shares of Edgewise Therapeutics?: During the last twelve months, Edgewise Therapeutics insiders bought shares 2 times. They purchased a total of 465,402 shares worth more than $5,100,965.10. During the last twelve months, insiders at the sold shares 16 times. They sold a total of 592,545 shares worth more than $11,865,014.27. The most recent insider tranaction occured on September, 23rd when General Counsel John R Moore sold 20,922 shares worth more than $578,074.86. Insiders at Edgewise Therapeutics own 24.1% of the company. Learn More about insider trades at Edgewise Therapeutics.
Information on this page was last updated on 9/23/2024.

Behrad Derakhshan Insider Trading History at Edgewise Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/2/2024	Sell	1,718	$18.91	$32,487.38	13,422
2/8/2024	Sell	4,600	$20.01	$92,046.00	7,020
5/2/2023	Sell	1,747	$8.90	$15,548.30	7,020

Behrad Derakhshan Buying and Selling Activity at Edgewise Therapeutics

Edgewise Therapeutics Company Overview

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Today's Range

Now: $32.05

$31.92

$32.61

50 Day Range

MA: $30.37

$16.86

$36.62

2 Week Range

Now: $32.05

$5.93

$38.12

Volume

3,693 shs

Average Volume

944,139 shs

Market Capitalization

$3.03 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.14

Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners

From Colonial Metals | Ad

Get Your Free Gold Guide

Behrad Derakhshan Biography and Net Worth

What is Behrad Derakhshan's net worth?

How old is Behrad Derakhshan?

What is Behrad Derakhshan's salary?

How do I contact Behrad Derakhshan?

Has Behrad Derakhshan been buying or selling shares of Edgewise Therapeutics?

Who are Edgewise Therapeutics' active insiders?

Are insiders buying or selling shares of Edgewise Therapeutics?